" class="no-js "lang="en-US"> GenScript Expands in Singapore to Provide Gene Synthesis
Friday, June 14, 2024

GenScript Expands Footprint in Singapore to Provide Premium Gene Synthesis Service

GenScript Biotech Corporation, the world’s leading provider of life-science research tools and services, announced the expansion of its Singapore facility to provide a premium gene synthesis service. The move adds an additional 976 square meters to the facility, bringing the total production footprint in Singapore to 3,500 square meters, and making it the third-largest GenScript facility worldwide. The expansion will also increase the total headcount at the Singapore facility to 150.

In February 2022, GenScript Asia-Pacific announced the opening of new recombinant protein production facility; now, that same facility will offer an advanced gene-synthesis service. This marks a significant expansion of the company’s advanced gene-synthesis capability and enables GenScript to provide the premium service levels required for novel vaccine and therapeutics development in life sciences. The Singapore facility houses state-of-the art automated workstations capable of synthesizing more than 400 genes per day. This automated technique enables precise measurement, eliminates human errors, and ensures a consistently high-quality product. The new facility aims to reduce project turnaround time for an increasingly global mix of customers while ensuring customer data are secured in Singapore. The capacity of the new facility is committed to support cell and gene therapy research and vaccine development programs.

“The expansion of our cutting-edge facility in Singapore boosts GenScript’s gene synthesis production capabilities, enabling us to meet the exacting demands of our regional biotech clients,” said Johnson Wang, president of GenScript Asia-Pacific. “The combination of GenScript’s fast-turnaround molecular biology services and the expertise of our experienced scientific and commercial teams positions GenScript to provide the best custom service to the region.”

“We understand that global supply is a huge challenge, and we remain committed to expanding our reach to meet the increasing demand for our customers worldwide. At GenScript, we take great pride in our ability to provide reliable and efficient solutions to our customers, and we are fully committed to delivering on this promise. As we continue to expand our global footprint, we remain dedicated to providing the highest-quality products and services to our customers, wherever they may be located,” said Dr. Ray Chen, president of GenScript’s Life Science Group.

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more